Hana Biosciences has submitted a new drug application for Zensana, an oral spray version of odansetron (Zofran).
Odansetron is one of the most commonly used antiemetics in cancer patients. Currently, it must be either injested orally as a tablet, oral solution, or orally desintigrating tablet. An oral spray might allow patients that have difficulty swallowing injest the medication more quickly, allowing faster relief of nausea and vomiting symptoms.
If the drug is approved, Hana plans to begin marketing the drug sometime next year.
